Advertisement
Mayo Clinic Proceedings Home

Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Mayo Clinic in Arizona Experience

      Abstract

      Objective

      To report the initial experience of treating recurrent Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) at Mayo Clinic in Arizona.

      Patients and Methods

      The study retrospectively reviewed FMTs performed at Mayo Clinic in Arizona between January 1, 2011, and January 31, 2013. All the recipients had multiple recurrent CDIs unresponsive to traditional antibiotic drug therapy. A standardized protocol was developed to identify patients, screen donors, perform FMT, and determine outcomes via telephone surveys.

      Results

      Thirty-one patients (mean ± SD age, 61.26±19.34 years) underwent FMT. Median time from index infection to FMT was 340 days. Ninety-seven percent (29 of 30) of patients reported substantial improvement or resolution of diarrhea (median time to improvement, 3 days), 74% (17 of 23) reported improvement or resolution of abdominal pain (median time to improvement, 3 days), and 55% (16 of 29) had improvement or resolution of fatigue (median time to improvement, 6 days). Three patients underwent repeated FMT owing to persistent symptoms; 2 reported improvement in diarrhea with the second therapy. No serious adverse events directly related to FMT were reported.

      Conclusion

      A standardized regimen of FMT for recurrent CDI is safe, is highly effective, and can be provided using a relatively simple protocol.

      Abbreviations and Acronyms:

      CDI (Clostridium difficile infection), FMT (fecal microbiota transplant), NAP1 (PCR ribotype 027/North American pulsed-field type 1)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hall I.C.
        • O'Toole E.
        Intestinal flora in the newborn infant with a description of a new pathogenic anaerobe, Bacillus difficile.
        Am J Dis Child. 1935; 49: 390-402
        • Bartlett J.G.
        • Chang T.W.
        • Gurwith M.
        • Gorbach S.L.
        • Onderdonk A.B.
        Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.
        N Engl J Med. 1978; 298: 531-534
        • Redelings M.D.
        • Sorvillo F.
        • Mascola L.
        Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.
        Emerg Infect Dis. 2007; 13: 1417-1419
        • Miller B.A.
        • Chen L.F.
        • Sexton D.J.
        • Anderson D.J.
        Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals.
        Infect Control Hosp Epidemiol. 2011; 32: 387-390
        • Khanna S.
        • Pardi D.S.
        • Aronson S.L.
        • et al.
        The epidemiology of community-acquired Clostridium difficile infection: a population-based study.
        Am J Gastroenterol. 2012; 107: 89-95
        • Garey K.W.
        • Ghantoji S.S.
        • Shah D.N.
        • et al.
        A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
        J Antimicrob Chemother. 2011; 66: 2850-2855
        • Surawicz C.M.
        • McFarland L.V.
        • Greenberg R.N.
        • et al.
        The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.
        Clin Infect Dis. 2000; 31: 1012-1017
        • Ghantoji S.S.
        • Sail K.
        • Lairson D.R.
        • DuPont H.L.
        • Garey K.W.
        Economic healthcare costs of Clostridium difficile infection: a systematic review.
        J Hosp Infect. 2010; 74: 309-318
        • Eiseman B.
        • Silen W.
        • Bascom G.S.
        • Kauvar A.J.
        Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.
        Surgery. 1958; 44: 854-859
        • Gough E.
        • Shaikh H.
        • Manges A.R.
        Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.
        Clin Infect Dis. 2011; 53: 994-1002
        • van Nood E.
        • Vrieze A.
        • Nieuwdorp M.
        • et al.
        Duodenal infusion of donor feces for recurrent Clostridium difficile.
        N Engl J Med. 2013; 368: 407-415
        • Kelly C.P.
        Fecal microbiota transplantation: an old therapy comes of age.
        N Engl J Med. 2013; 368: 474-475
        • Zipursky J.S.
        • Sidorsky T.I.
        • Freedman C.A.
        • Sidorsky M.N.
        • Kirkland K.B.
        Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection.
        Clin Infect Dis. 2012; 55: 1652-1658
        • Gallegos-Orozco J.F.
        • Paskvan-Gawryletz C.D.
        • Gurudu S.R.
        • Orenstein R.
        Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis.
        Rev Gastroenterol Mex. 2012; 77: 40-42
        • Rohlke F.
        • Surawicz C.M.
        • Stollman N.
        Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology.
        J Clin Gastroenterol. 2010; 44: 567-570
        • Yoon S.S.
        • Brandt L.J.
        Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients.
        J Clin Gastroenterol. 2010; 44: 562-566
        • Bakken J.S.
        Fecal bacteriotherapy for recurrent Clostridium difficile infection.
        Anaerobe. 2009; 15: 285-289
        • Huebner E.S.
        • Surawicz C.
        Treatment of recurrent Clostridium difficile diarrhea.
        Gastroenterol Hepatol. 2006; 2: 203-208
        • Rupnik M.
        • Wilcox M.H.
        • Gerding D.N.
        Clostridium difficile infection: new developments in epidemiology and pathogenesis.
        Nat Rev Microbiol. 2009; 7: 526-536
        • Louie T.J.
        • Miller M.A.
        • Mullane K.M.
        • et al.
        Fidaxomicin versus vancomycin for Clostridium difficile infection.
        N Engl J Med. 2011; 364: 422-431
        • Khoruts A.
        • Dicksved J.
        • Jansson J.K.
        • Sadowsky M.J.
        Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea.
        J Clin Gastroenterol. 2010; 44: 354-360
        • Hamilton M.J.
        • Weingarden A.R.
        • Unno T.
        • Khoruts A.
        • Sadowsky M.J.
        High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria.
        Gut Microbes. 2013; 4: 125-135
        • Garey K.W.
        • Sethi S.
        • Yadav Y.
        • DuPont H.L.
        Meta-analysis to assess risk factors for recurrent Clostridium difficile infection.
        J Hosp Infect. 2008; 70: 298-304
        • Hamilton M.J.
        • Weingarden A.R.
        • Sadowsky M.J.
        • Khoruts A.
        Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.
        Am J Gastroenterol. 2012; 107: 761-767
        • Surawicz C.M.
        • Brandt L.J.
        • Binion D.G.
        • et al.
        Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.
        Am J Gastroenterol. 2013; 108: 478-498
        • McGlone S.M.
        • Bailey R.R.
        • Zimmer S.M.
        • et al.
        The economic burden of Clostridium difficile.
        Clin Microbiol Infect. 2012; 18: 282-289